Drugs / talotrexin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00458744 | Feb 2007 → Jul 2008 | central nervous system neoplasm, childhood malignant neoplasm, leukemia, lymphoma | Children's Oncology Group | Withdrawn | No outcome recorded |
| Phase 1 | NCT00098514 | Dec 2003 → Mar 2007 | cancer of unknown primary site | Dana-Farber Cancer Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | talotrexin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00098514 ↗ |
| Known as | PT-523 | “A Phase I Study Of Talotrexin (PT-523) In Children And Adolescents With Recurrent Solid Tumors Or Recurrent/Refractory Leukemias” NCT00458744 ↗ |
| Route | Intravenous | “talotrexin IV over 5 minutes” NCT00098514 ↗ |